Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This trial will include patients who have a heart condition called atrial fibrillation.
Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart. Patients with atrial
fibrillation have an increased chance for a blood clot to form in the heart and move to other
blood vessels in the body and cause obstruction. This obstruction may damage tissue. For
example, a blood clot plugging a vessel in the brain could cause a stroke. Therefore,
patients with atrial fibrillation may be given anticoagulant (blood-thinning) tablets such as
warfarin or acenocoumarol.
The purpose of this study is to compare the safety and effectiveness of a new injectable
anticoagulant drug that is administered once weekly, SR34006 with warfarin or acenocoumarol
tablets.
Assignment to either SR34006 Injection or vitamin K antagonist (warfarin or acenocoumarol)
tablets will be purely by chance and will be known by both patients and their doctors.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Acenocoumarol Idraparinux SANORG 34006 Vitamin K Vitamins Warfarin